Participates in the formation of bones and the reconstruction of bone tissue after fracture, muscle contraction, nerve transmission, coagulation process and reduces the permeability of capillaries, etc.

It competes with p-aminobenzoic acid for dihydrofolate synthase, inhibiting bacterial synthesis of dihydrofolate; when used in combination with trimethoprim and sulfadiazine, it has a double blocking effect on the bacterial synthesis of tetrahydrofolate, enhancing the antibacterial effect.

It competes with p-aminobenzoic acid for dihydrofolate synthase, inhibiting bacterial synthesis of dihydrofolate; when used in combination with trimethoprim and sulfamethoxazole, it has a double blocking effect on the bacterial synthesis of tetrahydrofolate, enhancing the antibacterial effect.

By inhibiting the bacterial dihydrofolate reductase, it hinders the reduction of dihydrofolate to tetrahydrofolate; when used in combination with sulfamethoxazole and sulfadiazine, it has a double blocking effect on the bacterial synthesis of tetrahydrofolate, thereby enhancing the antibacterial effect.

This product is a medium-acting sulfonamide. It has antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Salmonella, Shigella and other Enterobacteriaceae, gonococci, meningococci, Haemophilus influenzae. In addition, it also has antimicrobial activity against Chlamydia trachomatis, Nocardia asteroides, Plasmodium and Toxoplasma in vitro. The antibacterial activity of this product is the same as that of sulfamethoxazole. However, in recent years, bacterial resistance to this product has increased, especially Streptococcus, Neisseria and Enterobacteriaceae. Sulfonamides are broad-spectrum antibacterial agents. This product is similar in structure to para-aminobenzoic acid (PABA), and can compete with PABA on dihydrofolate synthase in bacteria, thereby preventing PABA from being used as a raw material to synthesize folic acid required by bacteria, reducing the amount of metabolically active tetrahydrofolate, which is an essential substance for bacteria to synthesize purine, thymidine and deoxyribonucleic acid (DNA), thereby inhibiting the growth and reproduction of bacteria.

1. Completely or partially correct the central inhibitory effects of opioids, such as respiratory depression, sedation and hypotension. 2. It has a wake-promoting effect on animals with acute ethanol intoxication. 3. It is a pure opioid receptor antagonist and does not have the excitatory or morphine-like effects of other opioid receptor antagonists; it does not cause respiratory depression, psychotomimetic reactions or miotic reactions. 4. No drug tolerance, nor physiological or psychological dependence, has been observed. 5. It antagonizes the effects of opioids by competing for the same receptor sites.

1. Completely or partially correct the central inhibitory effects of opioids, such as respiratory depression, sedation and hypotension. 2. It has a wake-promoting effect on animals with acute ethanol intoxication. 3. It is a pure opioid receptor antagonist and does not have the excitatory or morphine-like effects of other opioid receptor antagonists; it does not cause respiratory depression, psychotomimetic reactions or miotic reactions. 4. No drug tolerance, nor physiological or psychological dependence, has been observed. 5. It antagonizes the effects of opioids by competing for the same receptor sites.